IV 
115TH CONGRESS 
1ST SESSION 
H. RES. 402 
Supporting the designation of July 2017 as Uterine Fibroids Awareness 
Month. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 22, 2017 
Mr. DAVID SCOTT of Georgia (for himself, Ms. FUDGE, and Ms. KELLY of 
Illinois) submitted the following resolution; which was referred to the 
Committee on Energy and Commerce 
RESOLUTION 
Supporting the designation of July 2017 as Uterine Fibroids 
Awareness Month. 
Whereas fibroids may cause significant morbidity through 
their presence in the uterus and pelvic cavity causing sig-
nificant pelvic pain, abnormal uterine bleeding, reproduc-
tive dysfunction, miscarriages, and even infertility; 
Whereas the pain, discomfort, stress, and other physical and 
emotional symptoms of living with fibroids may signifi-
cantly interfere with a woman’s quality of life, compro-
mising her ability to function normally, work or care for 
her family; and may lead to more severe health and 
wellness issues; 
Whereas uterine fibroids are the most prevalent medical con-
dition affecting women, with an estimated 30 percent of 
VerDate Sep 11 2014 
05:32 Jun 23, 2017
Jkt 069200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR402.IH
HR402
SSpencer on DSKBBV9HB2PROD with BILLS
•HRES 402 IH 
women developing a uterine fibroid by age 35, and 80 
percent of women developing a uterine fibroid by age 50; 
Whereas the exact number of affected women is unknown as 
detection and diagnosis is difficult as only 1 out of 4 
women who have a uterine fibroid tumor exhibit symp-
toms severe enough to require treatment; 
Whereas the overall incidence of uterine fibroid tumors is es-
timated to disproportionately and more severely impact 
Black and Hispanic women, resulting in an incidence rate 
that is 3 times greater in women with Black ancestry and 
2 times greater in Hispanic women compared to Cauca-
sian women; 
Whereas a hysterectomy, or removal of the uterus, is among 
the most common surgical treatments for uterine fibroids 
and more than 200,000 hysterectomies are performed 
each year to treat uterine fibroids, at an estimated an-
nual cost of more than $2 billion; 
Whereas uterine fibroid tumors were estimated to cost the 
United States $5.9 billion to $34.4 billion annually with 
an estimated annual lost work cost of $1.6 billion to 
$17.2 billion through absenteeism and short-term dis-
ability in women age 25 to 54; and 
Whereas public awareness and education campaigns on uter-
ine fibroids prevention, screening, and symptoms are held 
during the month of July each year: Now, therefore, be 
it 
Resolved, That the House of Representatives— 
(1) supports the goals and ideas of Uterine 
Fibroids Awareness Month; 
VerDate Sep 11 2014 
05:32 Jun 23, 2017
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\HR402.IH
HR402
SSpencer on DSKBBV9HB2PROD with BILLS
•HRES 402 IH 
(2) recognizes the disparity in incidence rates of 
African-American and Hispanic uterine fibroid pa-
tients; 
(3) recognizes the need for greater research, 
treatment, and care options regarding uterine 
leiomyoma; and 
(4) encourages the President to issue a procla-
mation calling upon the people of the United States 
to observe the month with appropriate awareness 
and educational activities. 
Æ 
VerDate Sep 11 2014 
05:32 Jun 23, 2017
Jkt 069200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\HR402.IH
HR402
SSpencer on DSKBBV9HB2PROD with BILLS